Global Muscle Spasticity Market - 2023-2030

Global Muscle Spasticity Market - 2023-2030

Global Muscle Spasticity Market reached US$ 4.2 billion in 2022 and is expected to reach US$ 7.7 billion by 2030, growing with a CAGR of 8.1% during the forecast period 2023-2030.

The market for treating muscle spasticity, which frequently results from neurological diseases such as multiple sclerosis, cerebral palsy, spinal cord injuries, and stroke, includes medications, medical devices, and therapies.

Age-related neurological disorders, which frequently result in muscle spasticity, are more common in older people. The need for treatments and management techniques grows along with the aging population. Greater access to medical services, diagnosis, and treatment for muscle spasticity encourages market expansion. This is especially true in emerging markets.

However, patient adherence to recommended treatments can be difficult, which has an impact on treatment results and market expansion. Certain patient populations may only use certain muscular spasticity treatments, especially medicines, due to safety concerns.

Dynamics

Increasing Research Activities

In May 2022, The first patient was enrolled in Saol Therapeutics' Phase 2 RAISE Spasticity Trial, the privately held, clinical-stage pharmaceutical business said today. In the RAISE Spasticity Trial, SL-1002, a unique, proprietary chemoneurolytic injectable, is being tested. It is currently being developed by Saol Therapeutics. To evaluate the safety, pharmacokinetics, and efficacy of SL-1002 in adult patients with limb spasticity, a double-blind, placebo-controlled, single ascending-dose escalation study is being conducted (NCT05311215).

The overall safety profile of SL-1002 following a single treatment exposure in contrast to placebo is the main outcome. Measures like the Tardieu scale, Clinical Global Impression of Change (CGI-C), and the Modified Ashworth Score (MAS) are examples of secondary endpoints, although they are not the only ones. Characterizing human pharmacokinetics and pharmacodynamics in relation to the metabolism and clearance of SL-1002 and its metabolites are additional secondary measurements.

The Increasing Treatment Options

Demyelination along the spinal cord and brain's motor neurons causes spasticity in MS patients. The minor stiffness brought on by spasticity can occasionally be advantageous since it gives people greater support when standing or turning. There are also drugs that may be more suitable for some people. Only after consulting with one's healthcare physician can these choices be taken. In severe cases that don't get better with conventional therapies, other therapies may be tried.

These include more long-term therapies as well as procedures that momentarily block the nerve and muscle (such as Botox or Myobloc injection). Examples include severing particular nerves or tendons through surgery and chemically deactivating a muscle. The following drugs can be used to treat spasticity: Valium (diazepam), Gablofen (baclofen injectable), Zanaflex tablets and capsules (tizanidine hydrochloride), and Baclofen (formerly marketed as Lioresal).

Increasing Patients with Muscle Spasticity

As per the article published in Stat Pearls in 2023, Brain injury, stroke, cerebral palsy, multiple sclerosis, trauma, and spinal cord injury are only a few of the many etiologies for spasticity. In a study that examined the prevalence of spasticity in stroke patients, 42.6% of stroke patients experienced spasticity, while 15.6% of patients experienced severe spasticity. 90% of the individuals in another study that examined the prevalence of spasticity in cerebral palsy had spastic subtypes.

Severe spasticity has a profound effect on a patient's life, affecting everything from daily living activities to mental health and even income. However, in individuals with weak limbs, particularly in the lower extremities, spasticity might be advantageous since it makes it easier for the patient to transfer or walk. For these reasons, assessing spasticity is crucial so that medical professionals may assess the efficacy of their treatment modalities.

Awareness and Education

Initiatives to raise awareness assist people with medical illnesses like muscle spasticity in understanding the nature of the condition, its causes, symptoms, and potential therapies. Patients who are more knowledgeable are better able to decide on their own care. Understanding the symptoms and indicators of muscular spasticity can help with an earlier diagnosis and intervention, which may enhance the effectiveness of the treatment and the patient's quality of life. Patients can choose the best course of action for their requirements after learning about all of the available treatment options, including drugs, treatments, and lifestyle modifications, thanks to awareness campaigns.

High Treatment Costs

Access to necessary medical care and pharmaceuticals may be hampered by high treatment expenses. This may result in poor or delayed medical care, which could exacerbate health consequences. Significant out-of-pocket costs, like as copayments, deductibles, and medication prices, could be incurred by patients and their families. Increased stress and financial instability may result from these financial responsibilities.

Low-income people and marginalized communities are disproportionately affected by high treatment costs, which can increase healthcare inequities. Health disparities and unequal access to care may result from this.

Side Effects and Tolerability

Many muscle relaxants used to treat spasticity can make a person feel sleepy or exhausted, which can impair their ability to carry out everyday tasks and operate cognitively. Some drugs may cause muscle weakness, which can make the symptoms of spasticity worse. Certain drugs can cause dizziness or lightheadedness, which makes it difficult for people to maintain balance and safely carry out daily chores.

Some treatments for muscle spasticity may have gastrointestinal side effects like nausea and vomiting. Some medicines have the potential to impair cognitive function, resulting in issues with memory and concentration. Rarely, people may develop allergic responses to drugs, which can range in severity from minor skin rashes to life-threatening anaphylactic shock.

Segment Analysis

The global muscle spasticity market is segmented based on drug type, route of administration, distribution channel and region.

Botulinum Toxin

As per the article published in Toxins in 2022, Cerebral palsy (CP), the most prevalent motor disability in childhood, is a disorder in which harm to the area of the brain that regulates body coordination eventually compromises the functionality of the musculoskeletal system. The majority of CP patients have spasticity, and one method for treating it is by focally injecting botulinum toxin type-A (BTX-A) into the afflicted muscles.

The goal of BTX-A is to reduce spasticity and enhance joint function by paralyzing the muscles, although it has been demonstrated to have some unanticipated side effects. Weakness and atrophy are the most overt symptoms of BTX-A injection on a muscle level. It's significant to note that extreme weakness, one of the most frequently reported negative effects, creates a separate risk factor for joint deterioration, which can then result in osteoarthritis.

Geographical Penetration

Advanced Healthcare Infrastructure

North America has been a dominant force in the global Muscle Spasticity market. Spasticity will affect between 25% and 43% of survivors in the first year following a stroke. More young stroke survivors experience it. Spasticity can make it very difficult to perform basic everyday functions including eating, dressing, and bathing. These restrictions may make it more difficult for caregivers and lower quality of life.

Due to the high frequency of diseases like multiple sclerosis and cerebral palsy, muscle spasticity is comparatively widespread in North America. The precise incidence varies by geography and demographics of the populace. The existence of underlying neurological disorders is the main cause of muscle spasticity in North America. For instance, MS has a significant role in the region's incidences of spasticity.

Muscle spasticity management can be greatly aided by the accessibility and affordability of rehabilitation treatments including physical therapy, occupational therapy, and speech therapy. Muscle spasticity's causes and treatments are still being studied. Numerous pharmaceutical and research organizations in North America are engaged in developing treatments and other interventions to enhance the lives of people with this condition.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global muscle spasticity market. Due to lockdowns, social segregation policies, and the redirection of healthcare resources to COVID-19 care, numerous research trials for novel medications or treatments for muscle spasticity postponed or discontinued. This postponed the availability of potentially groundbreaking treatments.

Telemedicine has become more widely used because of the pandemic, enabling medical professionals to remotely monitor and discuss with patients. Patients with muscle spasticity were affected by this change in healthcare delivery since they could now get care without making in-person office visits.

Russia-Ukraine War Impact Analysis

Access to necessary drugs and therapies for ailments like muscle spasticity may be very difficult in areas where there is conflict. Patients may encounter difficulties getting the required therapies, and healthcare facilities may struggle to maintain enough stocks of pharmaceuticals.

The healthcare system in a nation can be put under tremendous strain during wartime. The availability of specialized care for disorders like muscle spasticity may be hampered by delays caused by the redirection of resources that would otherwise be used to treat chronic conditions to emergency care.

By Drug Type
• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Others

By Route of Administration
• Oral
• Intramuscular
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Novartis AG, Beximco Pharmaceuticals Ltd., Zydus Cadila and others.

Why Purchase the Report?
• To visualize the global muscle spasticity market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of muscle spasticity market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global muscle spasticity market report would provide approximately 55 tables, 57 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies